Liquidia, UTC Each Claim Victory in Lung-Drug Patents Case (1)

Liquidia Corp. and United Therapeutics Corp., still navigating the fallout of a Delaware federal judge’s mixed ruling in a patent dispute over competing treatments for high blood pressure in the lungs, each cast the outcome as favorable despite uncertainty that’s not likely to abate in the near term.

Judge Richard G. Andrews, in a 54-page opinion issued Wednesday in the US District Court for the District of Delaware, canceled one UTC patent for Tyvaso but found Liquidia’s Yutrepia will cause doctors and patients to infringe another.

UTC failed to prove Yutrepia will infringe a patent for an improved ...